{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["43"],"submitter":["Werner B"],"pubmed_abstract":["<h4>Objective</h4>To investigate cell-free DNA (cfDNA) in plasma and ascites and its association with clinical outcomes (paracentesis-free interval, overall survival) and CA125 level in participants with advanced ovarian cancer, treated with palliative intraperitoneal bevacizumab to delay re-accumulation of ascites.<h4>Methods</h4>cfDNA was extracted from 0.3 to 1 mL samples from 20/24 participants of the REZOLVE trial. Standard and methylation-specific PCRs were performed to measure 3 biomarkers: total cfDNA (Alu), tumour-derived cfDNA (ctDNA, methylated IFFO1 promoter) and endothelium-derived cfDNA (ec-cfDNA, unmethylated CDH5 promoter). Values were correlated to clinical outcomes.<h4>Results</h4>cfDNA was detected in all samples, with higher yield in ascites (mean 669 ng/mL) than plasma"],"journal":["Translational oncology"],"pagination":["101914"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10966381"],"repository":["biostudies-literature"],"pubmed_title":["Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial."],"pmcid":["PMC10966381"],"pubmed_authors":["Cummins MM","Shannon C","Friedlander M","Yip S","Ford CE","Espinoza D","Ananda S","Warton K","Werner B","Mileshkin L","Sjoquist KM","Chang G"],"additional_accession":[]},"is_claimable":false,"name":"Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial.","description":"<h4>Objective</h4>To investigate cell-free DNA (cfDNA) in plasma and ascites and its association with clinical outcomes (paracentesis-free interval, overall survival) and CA125 level in participants with advanced ovarian cancer, treated with palliative intraperitoneal bevacizumab to delay re-accumulation of ascites.<h4>Methods</h4>cfDNA was extracted from 0.3 to 1 mL samples from 20/24 participants of the REZOLVE trial. Standard and methylation-specific PCRs were performed to measure 3 biomarkers: total cfDNA (Alu), tumour-derived cfDNA (ctDNA, methylated IFFO1 promoter) and endothelium-derived cfDNA (ec-cfDNA, unmethylated CDH5 promoter). Values were correlated to clinical outcomes.<h4>Results</h4>cfDNA was detected in all samples, with higher yield in ascites (mean 669 ng/mL) than plasma","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-07-09T10:39:24.033Z","creation":"2026-07-09T10:26:11.201Z"},"accession":"S-EPMC10966381","cross_references":{"pubmed":["38417292"],"doi":["10.1016/j.tranon.2024.101914"]}}